Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27708002 | 0.86 | TBXAS1 (0.52) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL4069939 | 0.82 | TDP1 (0.64) | HRH4HRH3TDP1L3MBTL1 | |
| SCHEMBL14524266 | 0.81 | TDP1 (0.64) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL27581879 | 0.81 | CYP2A6 (0.56) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL10670119 | 0.80 | CYP2A6 (0.54) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL8906004 | 0.80 | CYP2A6 (0.54) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL4774923 | 0.80 | CYP2A6 (0.69) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL2088563 | 0.80 | CYP2A6 (0.54) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL20412275 | 0.80 | CYP2A6 (0.74) | HRH4HRH3CHRNA7CYP2A6PTAFR | |
| SCHEMBL8200325 | 0.80 | CYP2A6 (0.68) | HRH4HRH3CHRNA7CYP2A6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894772-B2 | Flavor modulator having pyridine derivative or salt thereof as active ingredient | T. HASEGAWA CO., LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10882823-B2 | Flavor modulator having pyridine derivative or salt thereof as active ingredient | T. HASEGAWA CO., LTD. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-10836724-B2 | — | — | 2020-11-17 | — | — | US | disclosed |
| US-20180072670-A1 | FLAVOR MODULATOR HAVING PYRIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | T. HASEGAWA CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894772-B2 | Flavor modulator having pyridine derivative or salt thereof as active ingredient | TAS2R38, TAS1R1, TAS2R8 | HRH4 1127/4885HRH3 2015/4885CHRNA7 2546/4885 |
| US-10836724-B2 | — | TAS2R8, TAS2R38, IPO8 | HRH4 2269/4885HRH3 2735/4885CHRNA7 2424/4885 |
| US-10882823-B2 | Flavor modulator having pyridine derivative or salt thereof as active ingredient | TAS2R38, TAS1R1, TAS2R8 | HRH4 1127/4885HRH3 2015/4885CHRNA7 2546/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | HRH4 205/4885HRH3 191/4885CHRNA7 11/4885 |
| US-20180072670-A1 | FLAVOR MODULATOR HAVING PYRIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | TAS2R38, TAS1R1, TAS2R8 | HRH4 1127/4885HRH3 2015/4885CHRNA7 2546/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | HRH4 213/4885HRH3 110/4885CHRNA7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.